This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teicher, B. A. Articles by Frei, E. Search for Related Content PubMed PubMed Citation Articles by Teicher, B. A. Articles by Frei, E., III

Alkylating Agents: In Vitro Studies of Cross-Resistance Patterns in Human Cell Lines¹

Dana-Farber Cancer Institute, Boston, Massachusetts 02115

The alkylating agents represent one of the most important classes of antitumor agents and play a major role in combination with other agents in the curative chemotherapy of selected human cancers. By repeatedly exposing cells to escalating doses of an alkylating agent, we have developed four human tumor cell lines which are relatively stably resistant to the drug with which the culture was treated. The response of these cell lines to a variety of alkylating agents was compared to the response of the parent cell lines to the same drug. The Raji/HN2 line was 7-fold resistant to nitrogen mustard and about 3-fold resistant to 4-hydroxyperoxycyclophosphamide, but it was not resistant to N,N'-bis(2-chloroethyl)-N-nitrosourea (BCNU), melphalan (MEL), busulfan, trimethyleneiminethiophosphoramide, 4-hydroperoxyifosfamide, or cisplatin [cis-diamminedichloroplatinum(II)] (CDDP). The Raji/BCNU line was 5.3-fold resistant to BCNU and 4-fold resistant to both MEL and CDDP. The Raji/CP line was 7-fold resistant to CDDP and 3-fold resistant to both nitrogen mustard and BCNU, but it was not resistant to busulfan, trimethyleneiminethiophosphoramide, or 4-hydroperoxyifosfamide. The SCC-25/CP line, which was 12-fold resistant to CDDP, was 5-fold resistant to MEL and 3-fold resistant to 4-hydroxyperoxycyclophosphamide. The SCC-25/CP line was almost 24-fold resistant to methotrexate after 30-min treatment and about 7-fold resistant to methotrexate after continuous treatment. None of the other cell lines was resistant to methotrexate. The survival of SCC-25 and SCC-25/CP cells exposed to several antineoplastic agents was examined over several logs of survival. The SCC-25/CP cells are highly resistant to CDDP; the ratio of the slopes of the survival curves (SCC-25/CP to SCC-25) of the two lines was 43. At survivals of 1%, resistance to MEL and BCNU became evident in the SCC-25/CP line. At survivals of 0.1%, resistance to mitomycin C and, to a lesser degree, to Adriamycin and vincristine was evident. It is more difficult to produce resistance to alkylating agents, even with extended selection pressure, than to other antineoplastic drugs such as antimetabolites and natural products. We found no evidence of pleiotropic resistance in any alkylating agent-resistant cell line. Our results suggest that a judicious choice of alkylating agents given in sequential or concurrent combination may be a rational treatment strategy with potential applications in the clinic.

¹ This work is supported by National Cancer Institute Grant 1P01-CA38493.

² To whom requests for reprints should be addressed.

Received 3/14/86. Revised 6/ 9/86. Accepted 6/10/86.

This article has been cited by other articles:

				S. Gururangan, W. P. Petros, T. Y. Poussaint, M. L. Hancock, P. C. Phillips, H. S. Friedman, L. Bomgaars, S. M. Blaney, L. E. Kun, and J. M. Boyett Phase I Trial of Intrathecal Spartaject Busulfan in Children with Neoplastic Meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004) Clin. Cancer Res., March 1, 2006; 12(5): 1540 - 1546. [Abstract] [Full Text] [PDF]

				G. P. Canellos Clinical Research Saves Money: Reflections on High-Dose Therapy of Breast Cancer J. Clin. Oncol., July 1, 1999; 17(7): 1965 - 1965. [Full Text] [PDF]

				B. Brockstein and S. Williams High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow Stem Cells, January 1, 1996; 14(1): 79 - 89. [Abstract]

				B. Teicher, T. Herman, S. Holden, Y. Wang, M. Pfeffer, J. Crawford, and E Frei 3rd Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo Science, March 23, 1990; 247(4949): 1457 - 1461. [Abstract] [PDF]

				S. Kelley, A Basu, B. Teicher, M. Hacker, D. Hamer, and J. Lazo Overexpression of metallothionein confers resistance to anticancer drugs Science, September 30, 1988; 241(4874): 1813 - 1815. [Abstract] [PDF]